Masakazu Toi
A5091245889- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Estrogen and related hormone effects
- Angiogenesis and VEGF in Cancer
- Breast Lesions and Carcinomas
- Cancer, Hypoxia, and Metabolism
- Cancer Cells and Metastasis
- Cancer Genomics and Diagnostics
- Cancer-related Molecular Pathways
- Monoclonal and Polyclonal Antibodies Research
- Cancer Immunotherapy and Biomarkers
- MRI in cancer diagnosis
- Lung Cancer Research Studies
- Radiomics and Machine Learning in Medical Imaging
- Photoacoustic and Ultrasonic Imaging
- BRCA gene mutations in cancer
- Chronic Lymphocytic Leukemia Research
- Colorectal Cancer Treatments and Studies
- Inflammatory mediators and NSAID effects
- Cancer, Lipids, and Metabolism
- Immunotherapy and Immune Responses
- Medical Imaging Techniques and Applications
- Global Cancer Incidence and Screening
Kyoto University
2016-2025
Tokyo Metropolitan Komagome Hospital
2005-2025
Kyoto University Hospital
2015-2024
Miyoshi Kasei (Japan)
2024
Hyogo Medical University
2018-2024
Universal Scientific Education and Research Network
2023
Japan Breast Cancer Research Group
2005-2023
Sonnenhalde (Switzerland)
2023
Kyoto University of Education
2023
Ludwig-Maximilians-Universität München
2021
The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local regional therapies for early breast cancer, supporting less extensive surgery to axilla shorter durations radiation therapy. It refined its earlier approach classification management luminal disease in absence amplification or overexpression Human Epidermal growth factor Receptor 2 (HER2) oncogene, while retaining essentially unchanged...
<h2>ABSTRACT</h2> The 14th St Gallen International Breast Cancer Conference (2015) reviewed substantial new evidence on locoregional and systemic therapies for early breast cancer. Further experience has supported the adequacy of tumor margins defined as ‘no ink invasive or DCIS' safety omitting axillary dissection in specific cohorts. Radiotherapy trials support irradiation regional nodes node-positive disease. Considering subdivisions within luminal disease, Panel was more concerned with...
Patients who have residual invasive carcinoma after the receipt of neoadjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative breast cancer poor prognoses. The benefit adjuvant in these patients remains unclear.We randomly assigned 910 with HER2-negative (containing anthracycline, taxane, or both) to receive standard postsurgical treatment either capecitabine without (control). primary end point was disease-free survival. Secondary points included overall...
Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as monotherapy in combination with fulvestrant women hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced breast cancer previously treated endocrine therapy. Methods MONARCH 3 is double-blind, randomized phase III study of abemaciclib or placebo plus nonsteroidal aromatase inhibitor 493 postmenopausal HR-positive, HER2-negative who had no prior systemic therapy the...
Purpose MONARCH 2 ( ClinicalTrials.gov identifier: NCT02107703) compared the efficacy and safety of abemaciclib, a selective cyclin-dependent kinase 4 6 inhibitor, plus fulvestrant with alone in patients advanced breast cancer (ABC). Patients Methods was global, double-blind, phase III study women hormone receptor-positive human epidermal growth factor receptor 2-negative ABC who had progressed while receiving neoadjuvant or adjuvant endocrine therapy (ET), ≤ 12 months from end ET,...
Statistically significant overall survival (OS) benefits of CDK4 and CDK6 inhibitors in combination with fulvestrant for hormone receptor (HR)-positive, ERBB2 (formerly HER2)-negative advanced breast cancer (ABC) patients regardless menopausal status after prior endocrine therapy (ET) has not yet been demonstrated.To compare the effect abemaciclib plus vs placebo on OS at prespecified interim MONARCH 2 (338 events) HR-positive, ERBB2-negative that progressed during ET.MONARCH was a global,...
Abstract At the MONARCH 3 interim analysis, abemaciclib plus a nonsteroidal aromatase inhibitor (AI) significantly improved progression-free survival (PFS) and objective response rate (ORR) with tolerable safety profile as initial treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC). is randomized, phase III, double-blind study of abemaciclib/placebo (150 mg twice daily, continuous) AI (1 anastrozole or 2.5...
Background: The clinical outcome is generally positive for patients with node-negative breast carcinoma (i.e., those who do not have detectable metastases in the lymph nodes) been treated surgery or plus radiation therapy. In about 30% of patients, however, disease recurs, and they are at risk death. Determination valid new prognostic indicators would improve ability to identify high recurrence. Breast cancer can entail substantial development blood vessels within tumor tissue, it known that...
Many patients with HR+, HER2- early breast cancer (EBC) will not experience recurrence or have distant currently available standard therapies. However, up to 30% of high-risk clinical and/or pathologic features may recurrence, many in the first few years. Superior treatment options are needed prevent and development metastases for this group patients. Abemaciclib is an oral, continuously dosed, CDK4/6 inhibitor approved advanced (ABC). Efficacy safety abemaciclib ABC supported evaluation...
Angiogenesis is an independent prognostic indicator in breast cancer. In this report, the relationship between expression of vascular endothelial growth factor (VEGF; a selective mitogen for cells) and microvessel density was examined 103 primary cancers. The VEGF evaluated by immunocytochemical staining using anti-VEGF antibody. density, which determined immunostaining VIII antigen, VEGF-rich tumors clearly higher than that VEGF-poor (P < 0.01). There good correlation increment density....
Purpose Trastuzumab and pertuzumab are human epidermal growth factor receptor 2 (HER2) –targeted monoclonal antibodies, trastuzumab emtansine (T-DM1) is an antibody–drug conjugate that combines the properties of with cytotoxic activity DM1. T-DM1 demonstrated encouraging efficacy safety in a phase II study patients previously untreated HER2-positive metastatic breast cancer. Combination showed synergistic cell culture models had acceptable profile Ib study. Methods In MARIANNE study, 1,095...
AKT pathway activation is implicated in endocrine-therapy resistance. Data on the efficacy and safety of inhibitor capivasertib, as an addition to fulvestrant therapy, patients with hormone receptor-positive advanced breast cancer are limited.
Adjuvant abemaciclib combined with endocrine therapy (ET) previously demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS) and distant relapse-free (DRFS) hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer at the second interim analysis, however follow-up was limited. Here, we present results of prespecified primary outcome analysis an additional analysis.This global, phase III,...
APHINITY, at 45 months median follow-up, showed that pertuzumab added to adjuvant trastuzumab and chemotherapy significantly improved invasive disease-free survival (IDFS) (hazard ratio 0.81 [95% CI, 0.66 1.00], P = .045) for patients with early human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC), specifically those node-positive or hormone (HR)-negative disease. We now report the preplanned second interim overall (OS) descriptive updated IDFS analysis 74...